TY - JOUR
T1 - Comparative performance of pooled cohort equations and Framingham risk scores in cardiovascular disease risk classification in a slum setting in Nairobi Kenya
AU - Wekesah, Frederick M.
AU - Mutua, Martin K.
AU - Boateng, Daniel
AU - Grobbee, Diederick E.
AU - Asiki, Gershim
AU - Kyobutungi, Catherine K.
AU - Klipstein-Grobusch, Kerstin
N1 - Funding Information:
FMW received the Global Health Support Award for PhD from University Medical Center, Utrecht. The Awigen Collaborative Center is funded by the National Human Genome Research Institute (NHGRI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Office of the Director (OD) of the National Institutes of Health (NIH) of the United States of America (Grant #U54HG006938), as part of the H3Africa Consortium.
Funding Information:
FMW received the Global Health Support Award for PhD from University Medical Center, Utrecht. The Awigen Collaborative Center is funded by the National Human Genome Research Institute (NHGRI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Office of the Director (OD) of the National Institutes of Health (NIH) of the United States of America (Grant #U54HG006938), as part of the H3Africa Consortium.
Publisher Copyright:
© 2020 The Authors
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Background: Cardiovascular diseases (CVD) cause 18 million deaths annually. Low- and middle-income countries (LMICs) account for 80% of the CVD burden, and the burden is expected to grow in the region in the coming years. Screening for and identification of individuals at high risk for CVD in primary care settings can be accomplished using available CVD risk scores. However, few of these scores have been validated/recalibrated for use in sub-Saharan Africa (SSA). Methods: Pooled cohort equations (PCE) and Framingham risk scores for 10-year CVD risk were applied on 1960 men and women aged 40 years and older from the AWI-Gen (Africa, Wits-INDEPTH Partnership for GENomic studies) study 2015. Low, moderate/intermediate or high CVD risk classifications correspond to <10%, 10–20% and >20% chance of developing CVD in 10 years respectively. Agreement between the risk scores was assessed using kappa and correlation coefficients. Results: High CVD risk was 10.3% in PCE 2013, 0.4% in PCE 2018, 2.9% in Framingham and 3.6% in Framingham non-laboratory scores. Conversely, low CVD risk was 62.2% in PCE 2013 and 95.6% in PCE 2018, 84.0% and 80.1% in Framingham and Framingham non-laboratory scores, respectively. A moderate agreement existed between the Framingham functions (kappa = 0.64, 95% CI 0.59–0.68, correlation, rs = 0.711). There was no agreement between the PCE 2013 and 2018 functions (kappa = 0.05, 95% CI 0.04–0.06). Conclusions: Newer cohort-based data is necessary to validate and recalibrate existing CVD risk scores in order to develop appropriate functions for use in SSA.
AB - Background: Cardiovascular diseases (CVD) cause 18 million deaths annually. Low- and middle-income countries (LMICs) account for 80% of the CVD burden, and the burden is expected to grow in the region in the coming years. Screening for and identification of individuals at high risk for CVD in primary care settings can be accomplished using available CVD risk scores. However, few of these scores have been validated/recalibrated for use in sub-Saharan Africa (SSA). Methods: Pooled cohort equations (PCE) and Framingham risk scores for 10-year CVD risk were applied on 1960 men and women aged 40 years and older from the AWI-Gen (Africa, Wits-INDEPTH Partnership for GENomic studies) study 2015. Low, moderate/intermediate or high CVD risk classifications correspond to <10%, 10–20% and >20% chance of developing CVD in 10 years respectively. Agreement between the risk scores was assessed using kappa and correlation coefficients. Results: High CVD risk was 10.3% in PCE 2013, 0.4% in PCE 2018, 2.9% in Framingham and 3.6% in Framingham non-laboratory scores. Conversely, low CVD risk was 62.2% in PCE 2013 and 95.6% in PCE 2018, 84.0% and 80.1% in Framingham and Framingham non-laboratory scores, respectively. A moderate agreement existed between the Framingham functions (kappa = 0.64, 95% CI 0.59–0.68, correlation, rs = 0.711). There was no agreement between the PCE 2013 and 2018 functions (kappa = 0.05, 95% CI 0.04–0.06). Conclusions: Newer cohort-based data is necessary to validate and recalibrate existing CVD risk scores in order to develop appropriate functions for use in SSA.
KW - Framingham
KW - Kenya
KW - Pooled cohort equations
KW - Risk
KW - Risk assessment
KW - Risk communication
UR - http://www.scopus.com/inward/record.url?scp=85083770936&partnerID=8YFLogxK
U2 - 10.1016/j.ijcha.2020.100521
DO - 10.1016/j.ijcha.2020.100521
M3 - Article
C2 - 32373711
AN - SCOPUS:85083770936
SN - 2352-9067
VL - 28
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
M1 - 100521
ER -